期刊文献+

111例抗结核药致肝损伤住院病例调研分析 被引量:8

Clinical characterization for 111 cases of patients with antituberculosis drug-induced liver injury
在线阅读 下载PDF
导出
摘要 目的评价我国急性药物性肝损伤诊断标准与国际标准RUCAM评分系统的一致性。方法采用国际共识会议诊断标准和我国急性药物性肝损伤诊断标准对111例抗结核药致肝损伤病例进行回顾性调查分析。结果111例抗结核药导致的肝损伤中,101例符合美国药物性肝损伤网络提出的资料完整性标准。按照国际共识意见进行临床分型:肝细胞型81例(80.2%),胆汁淤积型16例(15.8%),混合型4例(4.0%)。采用RUCAM量化评分系统评分结果是:非常可能2例(2.0%),很可能63例(62.4%),可能32例(31.7%),不大可能4例(4.0%),无关0例;采用我国急性药物性肝损伤诊断标准对入选病例进行评定:确诊38例(37.6%),疑似57例(56.4%),排除6例(5.9%)。结论抗结核药致肝损伤的临床特点符合急性药物性肝损伤的临床规律。我国急性药物性肝损伤临床诊断方法简便,可操作性强,与RUCAM评分有较强的相关性。 Objective and international standard To evaluate the concordance between for RUCAM scoring system. Methods Chinese standard for the acute drug-induced liver injury The concordance between Chinese standard for the acute drug-induced liver injury and international standard for RUCAM scoring system was estimated by analyzing 111 cases of patients with antituberculosis (anti-TB) drug-induced liver injury. Results Among 111 inpatients, data for 101 cases were integrity according to the standard for American drug-induced liver injury network. According to clinical classification for international consensus view, there were 81 cases (80.2%) for hepatitis type, 16 cases ( 15.8% ) for cholestasis type, and 4 cases (4.0%) for mixed type. The results based on RUCAM scoring system were as follows: 2 cases (2.0%) were highly probably relevant, 63 cases (62.4%) probably relevant, 32 cases (31.7%) possibly rele- vant, 4 cases (4.0%) possibly irrelevant, 0 case irrelevant. The results based on Chinese standard for the acute druginduced liver injury were as follows: 38 cases (37.6%) were final diagnosis, 57 cases (56.4%) doubtful diagnosis, 6 cases (5.9%) depletion diagnosis. Conclusion Clinical characteristic of anti-TB drug-induced liver injury cases is consistent with clinical rule of acute drug-induced liver injury in China. The Chinese standard for acute drug-induced liver injury which is very useful for clinical doctor and easy to use in clinical practice is well correlated with RUCAM scoring system.
出处 《胃肠病学和肝病学杂志》 CAS 2009年第4期360-362,共3页 Chinese Journal of Gastroenterology and Hepatology
关键词 抗结核药 肝损伤 Antituberculosis drug Liver injury
  • 相关文献

参考文献10

  • 1许建明.全国多中心急性药物性肝损伤住院病例调研分析[J].中华消化杂志,2007,27(7):439-442. 被引量:88
  • 2许建明.急性药物性肝损伤诊治建议(草案)[J].中华消化杂志,2007,27(11):765-767. 被引量:351
  • 3Danan G, Benichou C. Causality assessment of adverse reactions to drugs-1. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries [ J]. J Clin Epidemiol, 1993, 46(11 ) : 1323-1330.
  • 4Benichou C. Criteria of drug-induced liver disorder. Report of an international consensus meeting [ J ]. J Hepatol, 1990, 11 (2) : 272-276.
  • 5Polson J, Lee WM. AASLD position paper: the management of acute liver failure [ J ]. Hepatology, 2005, 41 (5) : 1179-1197.
  • 6Rockey DC. Method of DILIN in Establishing Causality. AASLD-FDA- NIH-PhRMA. http://www.fda. gov/cder/livertox/presentations2006/Rockey. pdf.
  • 7uang YS. Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury [J]. Expert Opin Drug Metab Toxicol, 2007, 3 ( 1 ) : 1-8.
  • 8Wong WM, Wu PC, Yuen MF, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection [ J]. Hepatology, 2000, 31 ( 1 ) : 201-206.
  • 9Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement : hepatotoxicity of antituberculosis therapy [ J ]. Am J Respir Crit Care Med, 2006, 174 (8) : 935-952.
  • 10Bjomsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease [ J ]. Hepatology, 2005, 42 (2) : 481-459.

二级参考文献27

  • 1Agal S, Baijal R, Pramanik S, et al. Monitoring and management of antituberculosis drug induced hepatotoxicity. J Gastroenterol Hepatol, 2005, 20: 1745-1752.
  • 2Pittler MH, Ernst E. Systematic review: hepatotoxic events associated with herbal medicinal products. Aliment Pharmacol Ther, 2003, 18:451-471.
  • 3Schiano TD. Hepatotoxicity and complementary and alterative medicines. Clin Liver Dis, 2003, 7:453-473.
  • 4Furbee RB, Barlotta KS. Hepatotoxicity associated with herbal products. ClinLab Med, 2006, 26:227-241.
  • 5Benichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol, 1990, 11:272- 276.
  • 6Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis, 2002, 22: 145-155.
  • 7Bjomsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology, 2005, 42 : 481-489.
  • 8Andrade RJ, Lucerna MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology, 2005,129:512-521.
  • 9Navarro VJ, Senior JR. Drug related hepatotoxicity. N Engl J Med, 2006, 354:731-739.
  • 10Danan G, Benichou C. Causality assessment of adverse reactions to drugs-Ⅰ. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol, 1993, 46: 1323-1230.

共引文献423

同被引文献64

引证文献8

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部